Glycosylation status of vitamin D binding protein in cancer patients

Douglas S. Rehder, Randall W. Nelson, Chad Borges

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


On the basis of the results of activity studies, previous reports have suggested that vitamin D binding protein (DBP) is significantly or even completely deglycosylated in cancer patients, eliminating the molecular precursor of the immunologically important Gc macrophage activating factor (GcMAF), a glycosidase-derived product of DBP. The purpose of this investigation was to directly determine the relative degree of O-linked trisaccharide glycosylation of serum-derived DBP in human breast, colorectal, pancreatic, and prostate cancer patients. Results obtained by electrospray ionization-based mass spectrometric immunoassay showed that there was no significant depletion of DBP trisaccharide glycosylation in the 56 cancer patients examined relative to healthy controls. These results suggest that alternative hypotheses regarding the molecular and/or structural origins of GcMAF must be considered to explain the relative inability of cancer patient serum to activate macrophages.

Original languageEnglish (US)
Pages (from-to)2036-2042
Number of pages7
JournalProtein Science
Issue number10
StatePublished - Oct 2009


  • Cancer
  • GcMAF
  • Glycosylation
  • Vitamin D binding protein

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology


Dive into the research topics of 'Glycosylation status of vitamin D binding protein in cancer patients'. Together they form a unique fingerprint.

Cite this